More than 100 million people in the USA have diabetes or prediabetes and are at high risk
for developing cardiovascular disease. Current evidence-based guidelines support a
multifactorial approach in patients with diabetes, including lifestyle intervention and
pharmacological treatment of hyperglycemia, hypertension, and dyslipidemia. In addition,
recent cardiovascular outcome trials demonstrated that sodium-glucose cotransporter-2
inhibitors and glucagon-like peptide 1 receptor agonists improve cardiovascular outcomes …